Edition:
United Kingdom

Cytokinetics Inc (CYTK.OQ)

CYTK.OQ on NASDAQ Stock Exchange Global Select Market

7.20USD
23 Apr 2018
Change (% chg)

$0.05 (+0.70%)
Prev Close
$7.15
Open
$7.20
Day's High
$7.40
Day's Low
$7.10
Volume
52,833
Avg. Vol
122,189
52-wk High
$17.20
52-wk Low
$6.80

Latest Key Developments (Source: Significant Developments)

Cytokinetics Qtrly Net Loss Per Share $0.75
Thursday, 15 Feb 2018 

Feb 15 (Reuters) - Cytokinetics Inc ::CYTOKINETICS, INC. REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS.‍ENROLLMENT IN GALACTIC-HF ON TRACK UNDER COLLABORATION WITH AMGEN; FINALIZING PLANS FOR SECOND PHASE 3 CLINICAL TRIAL IN 2018​.‍COMPANY ANTICIPATES CASH REVENUE WILL BE IN RANGE OF $17 TO $23 MILLION FOR 2018​.QTRLY NET LOSS PER SHARE $0.75.Q4 EARNINGS PER SHARE VIEW $-0.70 -- THOMSON REUTERS I/B/E/S.FY2018 REVENUE VIEW $25.6 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Cytokinetics Announces Progress Against Vision 2020
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Cytokinetics Inc ::CYTOKINETICS ANNOUNCES PROGRESS AGAINST VISION 2020.CYTOKINETICS INC - ‍RESULTS FROM FOUR CLINICAL TRIALS OF CK-2127107 EXPECTED IN 2018​.CYTOKINETICS INC - RESULTS FROM FOUR CLINICAL TRIALS OF CK-2127107 EXPECTED IN 2018.CYTOKINETICS INC - ‍ENROLLMENT OF PATIENTS IN GALACTIC-HF IS ON TRACK IN 2018​.  Full Article

Cytokinetics Inc announces negative results from VITALITY-ALS
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Cytokinetics Inc :Cytokinetics announces negative results from VITALITY-ALS.Phase 3 clinical trial of Tirasemtiv in patients with ALS did not meet primary or secondary endpoints​.No new safety or tolerability findings related to Tirasemtiv were identified in VITALITY-ALS​.Believe that limitations of Tirasemtiv may be addressed with co's next-generation fast skeletal muscle activator, CK-2127107​.Have decided to suspend development of Tirasemtiv​.Limitations of Tirasemtiv may be addressed with co's "next-generation fast" skeletal muscle activator, CK-2127107​.Believe CK-2127107 will be better tolerated, potentially more effective than Tirasemtiv for ALS & look forward to phase 2 results in 2018​.  Full Article

Cytokinetics enters into second amendment to certain loan and security agreement
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Cytokinetics Inc ::Cytokinetics - ‍on Oct 27, entered into second amendment to certain loan and security agreement dated as of October 19, 2015 .Cytokinetics - ‍original loan agreement, as amended by amendment, provides for secured growth capital term loans of up to $50.0 million​.  Full Article

Cytokinetics reports Q3 loss of ‍$0.60/shr​
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Cytokinetics Inc :Cytokinetics, Inc. reports third quarter 2017 financial results.Q3 revenue $6.2 million versus I/B/E/S view $6.5 million.Cytokinetics Inc - qtrly loss per share ‍$0.60​.Cytokinetics Inc- ‍anticipates cash research and development expenses will be in range of $103 million to $107 million for 2017​.  Full Article

Cytokinetics announces dosing of first patient in Japan in phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure
Tuesday, 19 Sep 2017 

Sept 19 (Reuters) - Cytokinetics Inc :Cytokinetics announces dosing of first patient in Japan in GALACTIC-HF, phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure.Cytokinetics - ‍pharmacokinetics, pharmacodynamics, safety, tolerability data from trial were consistent with previously reported results from COSMIC-HF​.Cytokinetics Inc - ‍ coincident with patient dosing in galactic-hf, Amgen will make a $10 million milestone payment to Cytokinetics​.  Full Article

Cytokinetics Q2 loss per share $0.60
Wednesday, 2 Aug 2017 

Aug 2 (Reuters) - Cytokinetics Inc :Cytokinetics Inc reports second quarter 2017 financial results.Q2 revenue $3.1 million versus $5.8 million.Q2 loss per share $0.60.Q2 revenue view $8.3 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.57 -- Thomson Reuters I/B/E/S.  Full Article

Cytokinetics announces positive results from phase 2 trial of Omecamtiv Mecarbil
Wednesday, 2 Aug 2017 

Aug 2 (Reuters) - Cytokinetics Inc ::Cytokinetics announces positive results from phase 2 clinical trial of Omecamtiv Mecarbil in Japanese patients with heart failure.Cytokinetics announces positive results from phase 2 clinical trial of Omecamtiv Mecarbil in Japanese patients with heart failure.Cytokinetics inc - ‍company is eligible to earn $10 million milestone payment from amgen upon first patient dosing in Japan in phase 3 outcomes trial​.Cytokinetics inc - ‍phase 2 clinical trial of Omecamtiv Mecarbil in Japanese patients with heart failure has met its pharmacokinetic primary endpoint​.Cytokinetics inc - ‍phase 2 clinical trial demonstrated statistically significant improvements in systolic ejection time (set), a secondary endpoint​.Cytokinetics inc - ‍cytokinetics is eligible to earn a $10 million milestone payment from amgen upon first dosing of a patient in Japan in Galactic-Hf​.  Full Article

Cytokinetics announces start of FORTITUDE-ALS
Thursday, 27 Jul 2017 

July 27 (Reuters) - Cytokinetics Inc :Cytokinetics announces start of fortitude-als, a phase 2 clinical trial of ck-2127107 in patients with amyotrophic lateral sclerosis.  Full Article

Cytokinetics reports baseline data from first cohort of phase 2 clinical trial of ck-2127107 in patients with SMA
Wednesday, 5 Jul 2017 

July 5 (Reuters) - Cytokinetics Inc ::Cytokinetics announces baseline data from first cohort of phase 2 clinical trial of ck-2127107 in patients with sma.Cytokinetics -screen failures in cohort 1 primarily due to hfmse score that was either too high in ambulatory patients or too low in non-ambulatory patients.Cytokinetics - there were no statistically significant differences otherwise in baseline demographics of enrolled patients compared to screen failures.Cytokinetics - screen failures in cohort 1 primarily due to hfmse score that was either too high in ambulatory patients or too low in non-ambulatory patients.  Full Article

UPDATE 3-Novartis bets big on gene therapy with $8.7 bln AveXis deal

* Acquisition fuels busy year for biotechnology deal-making (Adds comments from analysts, details of advisers, shares)